Oncology Grand Rounds Series: Part 4 — Chronic Lymphocytic Leukemia

Video proceedings from the fourth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Paul M Barr, Ms Josie Bazemore, Dr Nitin Jain and Ms Lynn Rich.

1.6 contact hours

To complete the Post-test and Educational Assessment and Credit Form, click here. A statement of CNE credit will be issued for scores of 80% or better. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

Related links:

Home
CNE evaluation
CNE information and faculty disclosures
Select publications
PowerPoint slides

Introduction
Program overview: Dr Love
Newly Diagnosed Chronic Lymphocytic Leukemia (CLL): Observation versus Treatment
Case (Ms Bazemore): A woman in her early 60s with CLL with del(17p) and an IGHV mutation who was observed for 1 year before beginning treatment with ibrutinib
First-Line Treatment of CLL
Case (Ms Rich): A woman in her late 30s with newly diagnosed CLL who received FCR and has developed multiple infections after the completion of treatment
Case (Ms Bazemore): A man in his early 90s with CLL with unmutated IGHV who experienced a complete response to first-line obinutuzumab/chlorambucil
Relapsed/Refractory CLL
Case (Ms Rich): A man in his early 70s with relapsed CLL and a high tumor burden who initiated treatment with venetoclax
Case (Ms Bazemore): A man in his mid-60s with relapsed CLL who was admitted to receive venetoclax because of concerns with compliance
Case (Ms Rich): A man in his mid-70s with heavily pretreated CLL who was referred for hospice but is currently faring well off treatment